HeraMED Ltd
HMD
Company Profile
Business description
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.
Contact
201, 697 Burke Road
Suite 4
CamberwellVIC3124
AUST: +61 272511888
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.10 | 23.90 | -0.26% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 52,294.31 | 117.03 | -0.22% |
| NZX 50 Index | 13,643.86 | 87.56 | 0.65% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,863.60 | 19.10 | -0.22% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |